imlunestrant tosylate · Eli Lilly And Co · NDA 218881
Inluriyo
Earliest generic entry, as listed
11 Jul 2039
Blocked by patent: US 10654866, US 11117902.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10654866 | substance, product, use U-4278 | 11 Jul 2039 |
| US 11117902 | substance, product, use U-4278 | 11 Jul 2039 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 25 Sep 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218881 · 001 · RLD | tablet, oral | EQ 200MG BASE | 11 Jul 2039 |